Researchers at Charite-University Hospital Berlin and the University of Zurich have shown that p40, a protein subunit shared by IL-12 and IL-23, could be a new therapeutic target in Alzheimer's disease. The group now wants to find an industry partner to test late-stage or marketed p40-targeting therapies.